India Orders 300 Million Doses of Vaccines After Court Rebuke
(Bloomberg) --
India ordered 300 million doses of a coronavirus vaccine being developed by a local manufacturer, as Prime Minister Narendra Modi's government comes under pressure from the nation's Supreme Court to cover more of the population.
Hyderabad-based Biological-E Ltd. will be paid an advance of 15 billion rupees ($205 million), the government said in a statement Thursday. Phase 3 trials of the vaccine are currently on and the firm will prepare the shots between August and December.
Supreme Court Asks Modi to Make Inclusive India Vaccine Policy
The Supreme Court this week asked Modi's administration to prepare a vaccination policy that prices the shots equally for all and protects the poor. India's plans have had a rough ride, starting from Modi's much-lauded vaccine diplomacy during a brief lull between the first and far deadlier second coronavirus waves, to the current shortage for Indian citizens.
The Biological-E vaccine is a Receptor Binding Domain protein sub-unit vaccine. It's being developed together with Houston-based Baylor College of Medicine. When announcing trials last year, Biological-E said the two-dose vaccine will be spaced 28 days apart.
Due to the shortfall of doses, it's projected to take India about two years to cover 75% of its population with a two-dose shot at the current pace of vaccination. Modi's government says it will vaccinate every Indian by the end of 2021.
India's rush to procure vaccines means it may waive the indemnity clause for imported vaccines even as it has an in-principle agreement with Pfizer Inc. to start providing its shot against the Covid-19 virus by next month, The Times of India reported, citing a government official it didn't identify.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.